News Regeneron drug on track to be second FOP treatment There is only one approved drug for ultra-rare disease FOP on the market, but Regeneron is hoping to add a second.
News Lilly weakens on data reveal for oral obesity candidate Eli Lilly is preparing to file for approval of its oral weight-loss drug orforglipron before year-end, but not all are convinced by the data.
News AZ's bid for Fasenra approval in COPD falls short AstraZeneca has abandoned Fasenra development in COPD, but there is better news for the company with a new version of lupus drug Saphnelo.
News Pharma says UK is 'tumbling down' rankings for investment The UK is losing out to competitors in attracting investment in R&D, clinical trials, and capital projects, says a report from the ABPI pharma group.
News Lilly eyes earlier use of blood cancer drug Jaypirca Lilly's fast-growing blood cancer drug Jaypirca could gain more momentum thanks to a trial suggesting it could move into the first-line setting.
News Mixed data from lung cancer trials on show at WCLC Highlights of the WCLC show include new data for AstraZeneca's Tagrisso, Summit's ivonescimab, MSD/Daiichi's I-DXd, and BMS/Systimmune's iza-bren.
News Praxis soars on rare childhood epilepsy trial data Praxis looks like it could be filing for approval of two products next year, after its childhood epilepsy drug delivered a win in a pivotal trial.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
